GlaxoSmithKline Pharma Q2 net down 14.56% to Rs 98.29 crore

Tags: Companies
GlaxoSmithKline Pharmaceuticals today reported 14.56 per cent decline in net profit to Rs 98.29 crore for the quarter ended June 30 as the company continued to be impacted by the revamped price control order.

The company had reported a net profit of Rs 115.04 crore during the same period last year.

Net sales of the company increased 2.84 per cent to Rs 654.96 crore for the second quarter as compared to Rs 636.86 crore in the same period a year ago, GlaxoSmithKline Pharmaceuticals said in a BSE filing.

The company follows January-December financial year.

"The quarter continued to see the impact of the base effect of differential pricing cuts due to price control order, extending coverage to the National List of Essential Medicines (NLEM)," the company said.

Last year, Department of Pharmaceuticals had notified the Drugs (Prices Control) Order 2013 under which prices of 348 medicines in the NLEM have been brought under price control, thus replacing an earlier order of 1995 that regulated prices of only 74 bulk drugs.

Shares of GlaxoSmithKline Pharma were trading 0.84 per cent down at Rs 2,473.85 apiece during afternoon trade on the BSE.

EDITORIAL OF THE DAY

  • Jobless growth is the biggest challenge for the Narendra Modi government

    Quality jobs that pay handsomely is the biggest indicator of the health of an economy, especially in a developing country like India.

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Sandeep Bamzai

<b>Cut & Thrust:</b> At the cost of human life

Can we put a cost to human life? The incident ...

BK Chaturvedi

Committed, yet miles to go

Swachh Bharat is a mission to which everyone is committed. ...

Rajgopal Nidamboor

Soul consciousness and reason

The soul, in the philosophical writings of ancient Greece, has ...